<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00809146</url>
  </required_header>
  <id_info>
    <org_study_id>R01NS053031</org_study_id>
    <secondary_id>5U01NS056975-02</secondary_id>
    <nct_id>NCT00809146</nct_id>
  </id_info>
  <brief_title>Paramedic Treatment of Prolonged Seizures by Intramuscular Versus Intravenous Anticonvulsant Medications</brief_title>
  <acronym>RAMPART</acronym>
  <official_title>A Double-blind Randomized Clinical Trial of the Efficacy of IM Midazolam Versus IV Lorazepam in the Pre-hospital Treatment of Status Epilepticus by Paramedics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Robert Silbergleit</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this non-inferiority trial is to determine which type of routine care is the best
      for paramedics to stop someone from seizing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Seizures are a common medical problem. Although they can be frightening to watch, most
      seizures are brief and stop by themselves. Seizures that don't stop in seconds or minutes are
      a dangerous life-threatening medical emergency. Paramedics often have medications that can
      stop seizures, but the best way to give the medicines is not known. Paramedics often give
      medicine directly into a vein, which is called intravenous (IV) administration. This works
      well, but can be hard to do in a person who is seizing. It can also take some time and delay
      treatment. Another way to give the medicine is as a shot given into a muscle, which is called
      intramuscular (IM) administration. Giving the medicine this way is faster, but it may not
      stop the seizure as quickly.

      This clinical trial, the Rapid Anti-convulsant Medication Prior to ARrival Trial (RAMPART),
      is designed to figure out whether giving anti-seizure medicine works similarly well and more
      quickly when given through an IV or when given as a shot in the muscle. Two similar medicines
      will be used. Both are already used by paramedics in the field and by doctors in the hospital
      to stop seizures. One is commonly given by IV, and the other is commonly given as a shot in
      the muscle. In this study, the shot will be given using a device similar to an EpiPenâ€”which
      is an autoinjector used by people with severe allergies.

      Approximately 1,024 persons whose seizures are continuing after emergency medical service
      (EMS) arrival and who meet all eligibility criteria will be enrolled in the trial. Every
      participant will be treated with anti-seizure medicine by the paramedics. At random, half the
      participants will be in one group and half in another. Half the participants will receive the
      study medicine through an IV and will be given a shot in the muscle without medicine
      (placebo). The other half will receive the medicine as a shot in the muscle plus an IV
      without medicine (placebo).

      In September 2010, more rapid than expected enrollment made it feasible to increase the
      sample size of the study from 800 to 1,024 with the already available funding. The goals of
      the expansion were to enroll more pediatric subjects (since the trial was enrolling slightly
      fewer than anticipated) and to improve the power of the study to 90%, which was initially
      desired. It is important to understand that the extended enrollment was not a sample size
      re-estimation in any way. The opportunity to extend the trial is pragmatic, based solely on
      the early enrollment success of the trial. It is not informed by the planned interim analyses
      that have been performed, the results of which remain sequestered, and there have been no
      unscheduled interim analyses. The firewall that prevents the blinded leadership from any
      knowledge of the outcome data has been diligently maintained throughout the process of
      proposing and implementing this extension.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Termination of Seizures at ED Arrival With no Rescue Therapy Given</measure>
    <time_frame>Duration of prehospital care, outcome is determined upon arrival at the ED on the day of enrollment (average 20 minutes).</time_frame>
    <description>The primary outcome was termination of seizures before arrival in the emergency department (ED) without the need for the paramedics to provide rescue therapy. Subjects did not reach the primary outcome if they were having seizures on arrival in the emergency department or if they received rescue medication before arrival. Termination of seizures on arrival was determined according to the clinical judgment of the attending emergency physician and was based on examination of the subjects, their clinical course, and results of any routine diagnostic testing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Endotracheal Intubation Within 30 Min After ED Arrival</measure>
    <time_frame>anytime before 30 minutes after ED arrival</time_frame>
    <description>Endotracheal intubation performed or attempted by EMS or within 30 minutes after ED arrival is abstracted from the ED record physician and nursing records. Endotracheal intubation includes placement of a definitive tracheal airway (oro-, naso-, cricothyroidotomy, or tracheostomy) for support of respirations or protection of airway. Non-definitive and/or non-tracheal airways (oral or nasal airways, laryngeal mask airways, or esophageal obturator airways) are not included if the patient is not subsequently intubated unless specifically deemed to have been used in lieu of tracheal intubation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Hospitalized</measure>
    <time_frame>at ED disposition on day of enrollment</time_frame>
    <description>Hospital and ICU admission from the ED, and length of stay, is abstracted from the hospital admission record. ICU admission is recorded as occurring only if the ICU is the initial inpatient unit for the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Admitted to an Intensive Care Unit (ICU)</measure>
    <time_frame>at time of disposition on day of enrollment</time_frame>
    <description>Hospital and ICU admission from the ED, and length of stay, is abstracted from the hospital admission record. ICU admission is recorded as occurring only if the ICU is the initial inpatient unit for the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Recurrent Seizure Within 12 Hours After ED Arrival</measure>
    <time_frame>within 12 hours after ED arrival</time_frame>
    <description>Acute seizure recurrence is defined as any further convulsive or electrographic seizures occurring in the first 12 hours of hospitalization, if they require additional antiepileptic medications, in subjects that had been determined not to be having seizures on ED arrival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Hypotension</measure>
    <time_frame>participants were followed for the duration of hospital stay, an average of 6 days</time_frame>
    <description>Acute hypotension is defined as a systolic blood pressure of &lt; 90 mmHg sustained for greater than 5 minutes and for which the patient was treated with a continuous IV infusion of a vasopressor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With IM Injection-site Complications</measure>
    <time_frame>participants were followed for the duration of hospital stay, an average of 6 days</time_frame>
    <description>IM injection site complications are defined as any symptoms or signs of injury or reaction at the site of the study IM injection requiring treatment. This includes extensive hematoma requiring treatment (decompression, pressure dressings, or discontinuation of anticoagulant or antithrombotic medications). Treatment does not include imaging without other interventions. This definition also includes wound infection requiring antibiotic therapy, retained foreign bodies requiring exploration and removal, or other similar wound problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With IV Injection-site Complications</measure>
    <time_frame>participants were followed for the duration of hospital stay, an average of 6 days</time_frame>
    <description>IV insertion site complications are defined as any symptoms or signs of injury or reaction at the site of the study IV placed by paramedics and used for study medication. This includes thrombosis, phlebitis, or skin infection requiring specific treatment including compresses, antibiotics, or wound care.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Intensive Care Unit (ICU) Stay in Days</measure>
    <time_frame>participants were followed for the duration of hospital stay, an average of 6 days</time_frame>
    <description>Continuous days of initial ICU stay from time of admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay in Days</measure>
    <time_frame>participants were followed for the duration of hospital stay, an average of 6 days</time_frame>
    <description>Continuous acute care inpatient hospital days from day of admission until discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1023</enrollment>
  <condition>Status Epilepticus</condition>
  <arm_group>
    <arm_group_label>Intramuscular (IM) anticonvulsant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group gets active treatment with an anticonvulsant by the intramuscular route of administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous (IV) anticonvulsant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group gets active treatment with an anticonvulsant by the intravenous route of administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intramuscular route of active treatment</intervention_name>
    <description>IM administration by autoinjector of midazolam 5 mg for subjects under estimated weight of 40 kg or midazolam 10 mg for subjects with estimated weight of 40 kg or above, IV administration of matching volume of IV flush.</description>
    <arm_group_label>Intramuscular (IM) anticonvulsant</arm_group_label>
    <other_name>Autoinjector</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous route of active treatment</intervention_name>
    <description>IV administration of lorazepam 2 mg for subjects under estimated weight of 40 kg or midazolam 4 mg for subjects with estimated weight of 40 kg or above, IM administration by autoinjector of matching volume of saline.</description>
    <arm_group_label>Intravenous (IV) anticonvulsant</arm_group_label>
    <other_name>Ativan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Paramedics or reliable witnesses verify 5 minutes of either continuous seizure
             activity or of repeated convulsive seizure activity where the patient does not regain
             consciousness (operationally defined as meaningful speech or obeying commands) between
             seizures.

          -  Patient is still seizing at the time of paramedic treatment with study medications.

          -  Estimated weight equal to or greater than 13 kg.

          -  Subject to be transported to a RAMPART participating hospital.

        Exclusion Criteria:

          -  Major trauma as the precipitant of the seizure

          -  Hypoglycemia (as defined by local EMS protocol or a glucose &lt; 60 mg/dL)

          -  Known allergy to midazolam or lorazepam

          -  Cardiac arrest or heart rate (HR) &lt;40 beats per minute

          -  Sensitivity to benzodiazepines

          -  Medical alert tag marked with &quot;RAMPART declined&quot;

          -  Prior treatment of this seizure with diazepam autoinjector as part of another study

          -  Known pregnancy

          -  Prisoners
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Silbergleit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel H Lowenstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Valerie L Durkalski, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85742</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304-5777</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California-San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania/York</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University-Main Line</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas-Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://rampart.umich.edu</url>
    <description>RAMPART Study Public Information Web Site</description>
  </link>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2008</study_first_submitted>
  <study_first_submitted_qc>December 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2008</study_first_posted>
  <results_first_submitted>March 18, 2012</results_first_submitted>
  <results_first_submitted_qc>March 18, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 13, 2012</results_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Robert Silbergleit</investigator_full_name>
    <investigator_title>Principal Investigator, Professor</investigator_title>
  </responsible_party>
  <keyword>Status Epilepticus</keyword>
  <keyword>Emergency Medical Services</keyword>
  <keyword>Anticonvulsants</keyword>
  <keyword>Drug Administration Routes</keyword>
  <keyword>Seizures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Status Epilepticus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Lorazepam</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects treated for status epilepticus in the prehospital setting by paramedics were enrolled at the scene between June 2009 and January 2011. A total of 1023 subject enrollments represented 893 unique subjects with a reenrollment rate of 13%. RAMPART involved 4314 paramedics, 33 EMS agencies, and 79 receiving hospitals across the United States.</recruitment_details>
      <pre_assignment_details>Number of patients enrolled includes any repeat enrollments for those who presented to emergency medical services (EMS) with status epilepticus more than once. The number assigned to treatment in the intention-to-treat analysis includes every patient who was enrolled in the study but only the initial enrollment for those enrolled more than once.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intramuscular (IM) Anticonvulsant</title>
          <description>This group gets active treatment with an anticonvulsant by the intramuscular route of administration. IM administration by autoinjector of midazolam 5 mg for subjects under estimated weight of 40 kg or midazolam 10 mg for subjects with estimated weight of 40 kg or above, IV administration of matching volume of IV flush.</description>
        </group>
        <group group_id="P2">
          <title>Intravenous (IV) Anticonvulsant</title>
          <description>This group gets active treatment with an anticonvulsant by the intravenous route of administration. IV administration of lorazepam 2 mg for subjects under estimated weight of 40 kg or midazolam 4 mg for subjects with estimated weight of 40 kg or above, IM administration by autoinjector of matching volume of saline.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="448"/>
                <participants group_id="P2" count="445"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="448"/>
                <participants group_id="P2" count="445"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intramuscular (IM) Anticonvulsant</title>
          <description>This group gets active treatment with an anticonvulsant by the intramuscular route of administration. IM administration by autoinjector of midazolam 5 mg for subjects under estimated weight of 40 kg or midazolam 10 mg for subjects with estimated weight of 40 kg or above, IV administration of matching volume of IV flush.</description>
        </group>
        <group group_id="B2">
          <title>Intravenous (IV) Anticonvulsant</title>
          <description>This group gets active treatment with an anticonvulsant by the intravenous route of administration. IV administration of lorazepam 2 mg for subjects under estimated weight of 40 kg or midazolam 4 mg for subjects with estimated weight of 40 kg or above, IM administration by autoinjector of matching volume of saline.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="448"/>
            <count group_id="B2" value="445"/>
            <count group_id="B3" value="893"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" spread="22"/>
                    <measurement group_id="B2" value="44" spread="22"/>
                    <measurement group_id="B3" value="43" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0-5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11-20 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21-40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>41-60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;61 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="207"/>
                    <measurement group_id="B3" value="405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="250"/>
                    <measurement group_id="B2" value="238"/>
                    <measurement group_id="B3" value="488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="310"/>
                    <measurement group_id="B2" value="290"/>
                    <measurement group_id="B3" value="600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                    <measurement group_id="B2" value="224"/>
                    <measurement group_id="B3" value="453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="183"/>
                    <measurement group_id="B3" value="348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="448"/>
                    <measurement group_id="B2" value="445"/>
                    <measurement group_id="B3" value="893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dose tier</title>
          <description>All adults and those children with an estimated body weight of more than 40 kg received either 10 mg of intramuscular midazolam followed by intravenous placebo or intramuscular placebo followed by 4 mg of intravenous lorazepam. Children with an estimated weight of 13 to 40 kg received either 5 mg of intramuscular midazolam followed by intravenous placebo or intramuscular placebo followed by 2 mg of intravenous lorazepam.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>children with an estimated weight of 13 to 40 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Children estimated &gt;40kg and All Adults</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="386"/>
                    <measurement group_id="B2" value="386"/>
                    <measurement group_id="B3" value="772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of epilepsy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="293"/>
                    <measurement group_id="B2" value="295"/>
                    <measurement group_id="B3" value="588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not documented</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Final diagnosis</title>
          <description>Determined by medical record review at the time of hospital discharge</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Status epilepticus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="404"/>
                    <measurement group_id="B2" value="399"/>
                    <measurement group_id="B3" value="803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nonepileptic spell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Undetermined</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Termination of Seizures at ED Arrival With no Rescue Therapy Given</title>
        <description>The primary outcome was termination of seizures before arrival in the emergency department (ED) without the need for the paramedics to provide rescue therapy. Subjects did not reach the primary outcome if they were having seizures on arrival in the emergency department or if they received rescue medication before arrival. Termination of seizures on arrival was determined according to the clinical judgment of the attending emergency physician and was based on examination of the subjects, their clinical course, and results of any routine diagnostic testing.</description>
        <time_frame>Duration of prehospital care, outcome is determined upon arrival at the ED on the day of enrollment (average 20 minutes).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IM Midazolam</title>
            <description>Subjects in whom the study IM autoinjector contained active treatment with midazolam</description>
          </group>
          <group group_id="O2">
            <title>IV Lorazepam</title>
            <description>Subjects in whom the study IV infusion contained active treatment with lorazepam</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Termination of Seizures at ED Arrival With no Rescue Therapy Given</title>
          <description>The primary outcome was termination of seizures before arrival in the emergency department (ED) without the need for the paramedics to provide rescue therapy. Subjects did not reach the primary outcome if they were having seizures on arrival in the emergency department or if they received rescue medication before arrival. Termination of seizures on arrival was determined according to the clinical judgment of the attending emergency physician and was based on examination of the subjects, their clinical course, and results of any routine diagnostic testing.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
                <count group_id="O2" value="445"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="329"/>
                    <measurement group_id="O2" value="282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis of inferiority was tested with a one-sided z statistic. Sample size was estimated assuming independent proportions, 2 interim analyses, 70% control event rate; 90% power; a noninferiority margin of 10%; and a 1-sided test with type I error probability of 0.025. A sample size of 890 (445 per treatment group) was inflated by 15% (1024 subjects) to account for inadvertent repeated enrollment of the same subjects. Repeated enrollments of the same subject were not analyzed.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Assay sensitivity established by extensive review of lorazepam efficacy data. Noninferiority margin of 10% established by both clinical and statistical reasoning.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>one-sided z statistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>0.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Endotracheal Intubation Within 30 Min After ED Arrival</title>
        <description>Endotracheal intubation performed or attempted by EMS or within 30 minutes after ED arrival is abstracted from the ED record physician and nursing records. Endotracheal intubation includes placement of a definitive tracheal airway (oro-, naso-, cricothyroidotomy, or tracheostomy) for support of respirations or protection of airway. Non-definitive and/or non-tracheal airways (oral or nasal airways, laryngeal mask airways, or esophageal obturator airways) are not included if the patient is not subsequently intubated unless specifically deemed to have been used in lieu of tracheal intubation.</description>
        <time_frame>anytime before 30 minutes after ED arrival</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IM Midazolam</title>
            <description>Subjects in whom the study IM autoinjector contained active treatment with midazolam</description>
          </group>
          <group group_id="O2">
            <title>IV Lorazepam</title>
            <description>Subjects in whom the study IV infusion contained active treatment with lorazepam</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Endotracheal Intubation Within 30 Min After ED Arrival</title>
          <description>Endotracheal intubation performed or attempted by EMS or within 30 minutes after ED arrival is abstracted from the ED record physician and nursing records. Endotracheal intubation includes placement of a definitive tracheal airway (oro-, naso-, cricothyroidotomy, or tracheostomy) for support of respirations or protection of airway. Non-definitive and/or non-tracheal airways (oral or nasal airways, laryngeal mask airways, or esophageal obturator airways) are not included if the patient is not subsequently intubated unless specifically deemed to have been used in lieu of tracheal intubation.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
                <count group_id="O2" value="445"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Hospitalized</title>
        <description>Hospital and ICU admission from the ED, and length of stay, is abstracted from the hospital admission record. ICU admission is recorded as occurring only if the ICU is the initial inpatient unit for the patient.</description>
        <time_frame>at ED disposition on day of enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IM Midazolam</title>
            <description>Subjects in whom the study IM autoinjector contained active treatment with midazolam</description>
          </group>
          <group group_id="O2">
            <title>IV Lorazepam</title>
            <description>Subjects in whom the study IV infusion contained active treatment with lorazepam</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Hospitalized</title>
          <description>Hospital and ICU admission from the ED, and length of stay, is abstracted from the hospital admission record. ICU admission is recorded as occurring only if the ICU is the initial inpatient unit for the patient.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
                <count group_id="O2" value="445"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="258"/>
                    <measurement group_id="O2" value="292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Admitted to an Intensive Care Unit (ICU)</title>
        <description>Hospital and ICU admission from the ED, and length of stay, is abstracted from the hospital admission record. ICU admission is recorded as occurring only if the ICU is the initial inpatient unit for the patient.</description>
        <time_frame>at time of disposition on day of enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IM Midazolam</title>
            <description>Subjects in whom the study IM autoinjector contained active treatment with midazolam</description>
          </group>
          <group group_id="O2">
            <title>IV Lorazepam</title>
            <description>Subjects in whom the study IV infusion contained active treatment with lorazepam</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Admitted to an Intensive Care Unit (ICU)</title>
          <description>Hospital and ICU admission from the ED, and length of stay, is abstracted from the hospital admission record. ICU admission is recorded as occurring only if the ICU is the initial inpatient unit for the patient.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
                <count group_id="O2" value="445"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Recurrent Seizure Within 12 Hours After ED Arrival</title>
        <description>Acute seizure recurrence is defined as any further convulsive or electrographic seizures occurring in the first 12 hours of hospitalization, if they require additional antiepileptic medications, in subjects that had been determined not to be having seizures on ED arrival.</description>
        <time_frame>within 12 hours after ED arrival</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IM Midazolam</title>
            <description>Subjects in whom the study IM autoinjector contained active treatment with midazolam</description>
          </group>
          <group group_id="O2">
            <title>IV Lorazepam</title>
            <description>Subjects in whom the study IV infusion contained active treatment with lorazepam</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Recurrent Seizure Within 12 Hours After ED Arrival</title>
          <description>Acute seizure recurrence is defined as any further convulsive or electrographic seizures occurring in the first 12 hours of hospitalization, if they require additional antiepileptic medications, in subjects that had been determined not to be having seizures on ED arrival.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
                <count group_id="O2" value="445"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>All participants were included in this analysis of rate of recurrence because this is the most clinically relevant denominator, although, by definition, only participants who stopped could have recurrent seizures.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Hypotension</title>
        <description>Acute hypotension is defined as a systolic blood pressure of &lt; 90 mmHg sustained for greater than 5 minutes and for which the patient was treated with a continuous IV infusion of a vasopressor.</description>
        <time_frame>participants were followed for the duration of hospital stay, an average of 6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IM Midazolam</title>
            <description>Subjects in whom the study IM autoinjector contained active treatment with midazolam</description>
          </group>
          <group group_id="O2">
            <title>IV Lorazepam</title>
            <description>Subjects in whom the study IV infusion contained active treatment with lorazepam</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Hypotension</title>
          <description>Acute hypotension is defined as a systolic blood pressure of &lt; 90 mmHg sustained for greater than 5 minutes and for which the patient was treated with a continuous IV infusion of a vasopressor.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
                <count group_id="O2" value="445"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>1.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With IM Injection-site Complications</title>
        <description>IM injection site complications are defined as any symptoms or signs of injury or reaction at the site of the study IM injection requiring treatment. This includes extensive hematoma requiring treatment (decompression, pressure dressings, or discontinuation of anticoagulant or antithrombotic medications). Treatment does not include imaging without other interventions. This definition also includes wound infection requiring antibiotic therapy, retained foreign bodies requiring exploration and removal, or other similar wound problems.</description>
        <time_frame>participants were followed for the duration of hospital stay, an average of 6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IM Midazolam</title>
            <description>Subjects in whom the study IM autoinjector contained active treatment with midazolam</description>
          </group>
          <group group_id="O2">
            <title>IV Lorazepam</title>
            <description>Subjects in whom the study IV infusion contained active treatment with lorazepam</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With IM Injection-site Complications</title>
          <description>IM injection site complications are defined as any symptoms or signs of injury or reaction at the site of the study IM injection requiring treatment. This includes extensive hematoma requiring treatment (decompression, pressure dressings, or discontinuation of anticoagulant or antithrombotic medications). Treatment does not include imaging without other interventions. This definition also includes wound infection requiring antibiotic therapy, retained foreign bodies requiring exploration and removal, or other similar wound problems.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
                <count group_id="O2" value="445"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>10.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With IV Injection-site Complications</title>
        <description>IV insertion site complications are defined as any symptoms or signs of injury or reaction at the site of the study IV placed by paramedics and used for study medication. This includes thrombosis, phlebitis, or skin infection requiring specific treatment including compresses, antibiotics, or wound care.</description>
        <time_frame>participants were followed for the duration of hospital stay, an average of 6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IM Midazolam</title>
            <description>Subjects in whom the study IM autoinjector contained active treatment with midazolam</description>
          </group>
          <group group_id="O2">
            <title>IV Lorazepam</title>
            <description>Subjects in whom the study IV infusion contained active treatment with lorazepam</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With IV Injection-site Complications</title>
          <description>IV insertion site complications are defined as any symptoms or signs of injury or reaction at the site of the study IV placed by paramedics and used for study medication. This includes thrombosis, phlebitis, or skin infection requiring specific treatment including compresses, antibiotics, or wound care.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
                <count group_id="O2" value="445"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Intensive Care Unit (ICU) Stay in Days</title>
        <description>Continuous days of initial ICU stay from time of admission</description>
        <time_frame>participants were followed for the duration of hospital stay, an average of 6 days</time_frame>
        <population>All participants with ICU length of stay data</population>
        <group_list>
          <group group_id="O1">
            <title>IM Midazolam</title>
            <description>Subjects in whom the study IM autoinjector contained active treatment with midazolam</description>
          </group>
          <group group_id="O2">
            <title>IV Lorazepam</title>
            <description>Subjects in whom the study IV infusion contained active treatment with lorazepam</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Intensive Care Unit (ICU) Stay in Days</title>
          <description>Continuous days of initial ICU stay from time of admission</description>
          <population>All participants with ICU length of stay data</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="9.5"/>
                    <measurement group_id="O2" value="4.1" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.09</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospital Stay in Days</title>
        <description>Continuous acute care inpatient hospital days from day of admission until discharge</description>
        <time_frame>participants were followed for the duration of hospital stay, an average of 6 days</time_frame>
        <population>All subjects with hospital length of stay data</population>
        <group_list>
          <group group_id="O1">
            <title>IM Midazolam</title>
            <description>Subjects in whom the study IM autoinjector contained active treatment with midazolam</description>
          </group>
          <group group_id="O2">
            <title>IV Lorazepam</title>
            <description>Subjects in whom the study IV infusion contained active treatment with lorazepam</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospital Stay in Days</title>
          <description>Continuous acute care inpatient hospital days from day of admission until discharge</description>
          <population>All subjects with hospital length of stay data</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="251"/>
                <count group_id="O2" value="285"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="10.0"/>
                    <measurement group_id="O2" value="5.5" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events were collected through subject end of study (emergency department or hospital discharge).</time_frame>
      <desc>Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.</desc>
      <group_list>
        <group group_id="E1">
          <title>IM Midazolam</title>
          <description>Subjects in whom the study IM autoinjector contained active treatment with midazolam</description>
        </group>
        <group group_id="E2">
          <title>IV Lorazepam</title>
          <description>Subjects in whom the study IV infusion contained active treatment with lorazepam</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="137" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="156" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Hyperglycemic hyperosmolar nonketotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Vomiting/Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol/Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis/SIRS/organ failure</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Pneumonia/ Aspiration pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Brain mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Cerebral hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Ischemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Subarachnoid hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Pseudoseizures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure, acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory depression</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Apnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Post-extubation stridor/airway obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Stridor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Toxic epidermal necrolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting/Nausea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Silbergleit MD, Principal Investigator</name_or_title>
      <organization>University of Michigan</organization>
      <phone>734-232-2142</phone>
      <email>robie@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

